Showing 1651-1660 of 2150 results for "".
- Oculus Announces Parnership with Luvo to Offer New IPL and RF Devices for the US Ophthalmic Markethttps://modernod.com/news/oculus-announces-parnership-with-luvo-to-offer-new-ipl-and-rf-devices-for-the-us-ophthalmic-market/2481853/Oculus has announced a strategic partnership with Luvo to bring new specialty care devices to the US optometry and ophthalmology market. As part of the deal, Oculus is launching the Luvo Lucent and Darwin with Intense Pulse Light and Radio Frequency therapy, which are designed to e
- European Medicines Agency Accepts Iveric Bio’s Marketing Authorization Application for Avacincaptad Pegol for GAhttps://modernod.com/news/european-medicines-agency-accepts-iveric-bios-marketing-authorization-application-for-avacincaptad-pegol-for-geographic-atrophy/2481780/Two weeks after receiving FDA approval, the European Medicines Agency (EMA) has accepted for regulatory review Iveric Bio's marketing authorization application (MAA) for avacincaptad pegol (ACP), an investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) seco
- Glaukos Enters into a Collaboration and Marketing Agreement with Radius XRhttps://modernod.com/news/glaukos-enters-into-a-collaboration-and-marketing-agreement-with-radius-xr/2481728/Glaukos announced that it has entered into a collaboration and marketing agreement with Radius XR, whereby Glaukos will become the exclusive sales agent to market, promote, and solicit orders for the Radius XR wearable patient engagement and diagnostic system within the United States. Radius
- Novaliq Plans to File a Marketing Authorization Application for CyclASol in the EU for Dry Eye Diseasehttps://modernod.com/news/novaliq-plans-to-file-a-markting-authorization-application-for-cyclasol-in-the-eu-for-the-treatment-of-dry-eye-disease-in-july-2023/2481396/Novaliq announced its plans for filing a marketing authorization application (MAA) CyclASol (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED), in the European Union. The Committee for Medicinal Products for H
- Market Scope: Lens-Based Procedures Will Push Retail Refractive Surgery Market to $12 Billionhttps://modernod.com/news/market-scope-lens-based-procedures-will-push-retail-refractive-surgery-market-to-12-billion/2481338/Market Scope forecasts that the global refractive surgery industry will generate $12 billion in total retail revenue in 2027—up from $8.9 billion in 2022—for a compound growth rate of 6.2 percent. The health care research company expects revenue at the manufacturer level to
- Outlook Therapeutics Announces Validation of Marketing Authorization Application by the EMA for ONS-5010 for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-validation-of-marketing-authorization-application-by-the-european-medicines-agency-for-ons-5010-as-a-treatment-for-wet-amd/2481308/Outlook Therapeutics announced the validation of its marketing authorization application (MAA) by the European Medicines Agency (EMA) for ONS-5010 / Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degener
- Lucentis Biosimilar Ranivisio Receives Marketing Authorization from European Commissionhttps://modernod.com/news/european-commission-grants-marketing-authorization-for-ranivisio-for-amd/2481057/Teva Pharmaceuticals announced that it has received marketing authorization from the European Commission for Ranivisio (ranibizumab), a biosimilar of Lucentis. The authorization includes all five indications for which Lucentis is authorized in adults.
- LKC Appoints New Members of Sales and Marketing Leadershiphttps://modernod.com/news/lkc-appoints-new-members-of-sales-and-marketing-leadership/2480999/LKC Technologies, a provider of electroretinography devices, announced the hiring of two industry professionals to lead their strategic efforts to expand its foothold in the US optometric market. Gary VanMatre was appointed Vice President, US Sales, and will lead a geographica
- NovaBay Pharmaceuticals Targets New Market with Antimicrobial Avenova Lid and Lash Spray for Lash Extensionshttps://modernod.com/news/novabay-pharmaceuticals-targets-new-market-with-antimicrobial-avenova-lid-and-lash-spray-for-lash-extensions/2480997/NovaBay Pharmaceuticals announced the launch of a new marketing campaign targeting the large and growing number of women who wear eyelash extensions. This campaign represents the first step in a larger growth initiative to introduce the Avenova brand to an new group of consumers.</
- Global Data: Increasing Cataract Surgical Rates Will Drive Artificial Lenses Market to Reach $4.7 Billion by 2030https://modernod.com/news/global-data-increasing-cataract-surgical-rates-will-drive-artificial-lenses-market-to-reach-47-billion-by-2030/2480953/The global market for IOLs is forecast by GlobalData to steadily grow from $4.3 billion in 2021 to $4.7 billion by the end of the decade. The data and analytics company notes that this growth is primarily driven by the growing capacity of many hospitals and clinics across all regions to perform m